2025
Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline
Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.
Eli Lilly Acquires Scorpion Therapeutics in $2.5 Billion Deal to Boost Breast Cancer Treatment Options
Eli Lilly, Scorpion Therapeutics, breast cancer, PI3Kα inhibitor, STX-478, oncology pipeline, targeted therapy
Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma
Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25
Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal
Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder
Gilead and LEO Pharma Collaborate on STAT6 Inflammatory Disease Programmes
Gilead Sciences, LEO Pharma, STAT6, inflammatory diseases, partnership, oral formulations, dermatology
Regor’s Obesity Pill RGT-075 Shows Moderate Weight Loss in Phase 2a, Advances to Phase 2b Trial
RGT-075, obesity treatment, GLP-1 receptor agonist, oral medication, Phase 2a results, Phase 2b trial
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A
Tenpoint Therapeutics Prepares for 2026 Market Launch Following Successful Phase 3 Trial of BRIMOCHOL PF for Presbyopia Treatment
Tenpoint Therapeutics, BRIMOCHOL PF, Presbyopia treatment, Phase 3 trial, Combination eye drop, 2026 market launch
Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy
Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases